Balancing risk and benefit in venous thromboembolism trials: Concept for a bivariate endpoint trial design and analytic approach

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 8, 2013, Pages 1443-1448

  Kittelson, J M ^a   Spyropoulos, A C ^b   Halperin, J L ^c   Kessler, C M ^d   Schulman, S ^e   Steg, G ^f   Turpie, A G G ^e   Cutler, N R ^g   Hiatt, W R ^a   Goldenberg, N A ^h  

^a UNIVERSITY OF COLORADO   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e MCMASTER UNIVERSITY   (Canada)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g Worldwide Clinical Trials   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulants; Safety; Treatment efficacy; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; DABIGATRAN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL DECISION MAKING; DRUG EFFICACY; DRUG SAFETY; EXPERIMENTAL THERAPY; HEALTH CARE QUALITY; HIGH RISK PATIENT; HUMAN; INDIVIDUALIZATION; LUNG EMBOLISM; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; STUDY DESIGN; TREATMENT DURATION; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; SAFETY; TREATMENT EFFICACY; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; HEMORRHAGE; HUMANS; MORPHOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 84881582352     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12324     Document Type: Review

References (11)

1. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thrombo-embolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-56.
2. EINSTEIN-PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-97.
3. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-75.
4. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: 297-305.
5. Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 2012; 125: 2298-307.
6. Connolly SJ, Eikelboom JW, Ng J, Hirsh J, Yusuf S, Pogue J, de Caterina R, Hohnloser S, Hart RG; ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) Steering Committee and Investigators. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med 2011; 155: 579-86.
7. McClure LA, Brown MB. A likelihood approach to analyzing clinical trial data when treatments favor different outcomes. Contemp Clin Trials 2006; 27: 340-52.
8. Kosorok MR, Yuanjun S, De Mets DL. Design and analysis of group sequential clinical trials with multiple primary endpoints. Biometrics 2004; 60: 134-45.
9. Zhao L, Hu XJ, Lagakos SW. Statistical monitoring of clinical trials with multivariate response and/or multiple arms: a flexible approach. Biostatistics 2009; 10: 310-23.
10. Tripputi M. Use of Mediation in Designing Clinical Trials with two Primary Endpoints. PhD Dissertation. George Washington University (2009).
11. Goldenberg NA, Tripputi M, Crowther M, Abshire TC, DiMichele D, Manco-Johnson MJ, Hiatt WR. The "parallel-cohort RCT": novel design aspects and application in the Kids-DOTT trial of pediatric venous thromboembolism. Contemp Clin Trials 2010; 31: 131-3.